| pubmed-article:1712606 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C0238451 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C0005740 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C0053334 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:1712606 | lifeskim:mentions | umls-concept:C1517942 | lld:lifeskim |
| pubmed-article:1712606 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1712606 | pubmed:dateCreated | 1991-8-20 | lld:pubmed |
| pubmed-article:1712606 | pubmed:abstractText | 127 men with previously untreated non-seminomatous germ cell tumours (NSGCT) of the testis were given BEP chemotherapy (bleomycin, etoposide and cisplatin) between 1979-1986. Long-term follow-up (median 65 months) has shown an overall 5 year survival of 87.2% (95% confidence limits 81.1%-93.3%). Outcome was related to both tumour volume and serum marker levels of alpha-fetoprotein (alpha FP) and beta human chorionic gonadotropin (HCG), with 5 year actuarial survivals of 97.8%, 72.2% and 26.7% respectively for small, large and very large volume disease defined by Medical Research Council criteria, and 91.2% and 60.8%, respectively, for men with low (alpha FP less than or equal to 500 kU/l and HCG less than or equal to 1000 iU/l) or high serum marker levels. 79 men (62%) had a complete radiological and serum marker response to chemotherapy alone; residual masses postchemotheraphy were resected in 39 patients (31%), showing undifferentiated tumour in only 6 (15%). 23 of the 127 patients (18%) failed to respond or developed recurrent disease after BEP; only 5 were successfully salvaged. Myelotoxicity of treatment was mild with grade 4 toxicity in 2% of chemotherapy courses and 3 episodes of neutropenic sepsis. Mean glomerular filtration rates fell by 15.6% between courses 1 and 4 of BEP. Bleomycin pneumonitis developed in 13% of cases with 1 fatality. So far 21 men have had children following chemotherapy, but semen analysis 12 months or more (median 36 months) after treatment showed azoospermia in 11 out of 54 (20%) men tested. BEP chemotherapy can be regarded as standard treatment for patients with metastatic NSGCT in low-risk categories, but more intensive therapy is required for advanced presentations. Strategies to develop "risk related" treatment are under investigation. | lld:pubmed |
| pubmed-article:1712606 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712606 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1712606 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712606 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1712606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712606 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1712606 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1712606 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:JayGG | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:HorwichAA | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:HendryW FWF | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:PeckhamM JMJ | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:DearnaleyD... | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:NichollsJJ | lld:pubmed |
| pubmed-article:1712606 | pubmed:author | pubmed-author:A'HernRR | lld:pubmed |
| pubmed-article:1712606 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1712606 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:1712606 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1712606 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1712606 | pubmed:pagination | 684-91 | lld:pubmed |
| pubmed-article:1712606 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:meshHeading | pubmed-meshheading:1712606-... | lld:pubmed |
| pubmed-article:1712606 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1712606 | pubmed:articleTitle | Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. | lld:pubmed |
| pubmed-article:1712606 | pubmed:affiliation | Department of Radiotherapy and Oncology, Royal Marsden Hospital, Sutton, Surrey, U.K. | lld:pubmed |
| pubmed-article:1712606 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1712606 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1712606 | lld:pubmed |
